Rituximab conjugate - BioIntegrator

Drug Profile

Rituximab conjugate - BioIntegrator

Alternative Names: Aurixim® antibody conjugate; CON-4619

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioIntegrator
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Recurrent, Second-line therapy or greater) in Russia (IV, Infusion)
  • 28 Oct 2016 Biointegrator initiates enrolment in a phase I trial in Haematological malignancies in Russia (unspecified route)before October 2016 (BioIntegrator pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top